SCHEMBL6574032

SCHEMBL6574032

CCOC(=O)c1ccccc1S(=O)(=O)Nc1ccc(C)c(NC(=O)Cc2ccc(C#N)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 5/20 0.43
RORC P51449 4/20 0.43
TSHR P16473 2/20 0.43
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
IDH1 O75874 1/20 0.40
LMNA P02545 2/20 0.39
MGAT2 Q10469 1/20 0.39
MCL1 Q07820 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
MAPK10 P53779 1/20 0.39
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764538 0.85 F2 (0.43) HIF1ATSHRMAPTKMT2AMEN1
SCHEMBL6574056 0.83 RORC (0.45) RORCIDH1LMNAMGAT2MCL1
SCHEMBL6766536 0.82 HDAC1 (0.52) RORCMAPTKMT2AMEN1LMNA
SCHEMBL6574325 0.79 LMNA (0.44) RORCMAPTKMT2AMEN1IDH1
SCHEMBL6571783 0.78 LMNA (0.51) HIF1ARORCMAPTKMT2AMEN1
SCHEMBL6765129 0.77 MGAT2 (0.56) RORCLMNAMGAT2ALDH1A1HPGD
SCHEMBL6572898 0.77 IDH1 (0.40) RORCIDH1LMNAALDH1A1
SCHEMBL6762133 0.75 POLB (0.53) RORCKMT2AMEN1LMNAMCL1
SCHEMBL6766083 0.74 HDAC1 (0.51) RORCLMNAMCL1
SCHEMBL6571948 0.72 HDAC1 (0.48) RORCKMT2AMEN1LMNAMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040248897-A1 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-12-09 US disclosed
EP-1414790-A1 SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-05-06 EP disclosed
WO-2003000653-A1 SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248897-A1 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions NAT1, CYP3A5, CYP3A7 HIF1A 2834/4885RORC 1596/4885TSHR 3214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.